The North America Smart Inhalers Market would witness market growth of 23.3% CAGR during the forecast period (2021-2027).
The growth in air pollution generated by naturally occurring phenomena as well as pollution-induced by manmade sources is a major factor contributing to the rise in COPD and asthma prevalence. Ozone, which is found in smog, and particulate matter, which is found in smoke, haze, and dust, are two major air pollutants that aggravate asthma. As the amount of ozone and particle matter in the air rises, the likelihood of developing asthma symptoms rises at an alarming rate. As a result, an increase in air pollution is predicted to directly contribute to a spike in asthma and COPD cases, propelling the market forward.
More technological capabilities are being introduced to smart inhalers on a daily basis, offering better and more comprehensive asthma management. Asthma patients will benefit from smart inhalers because these inhalers will make asthma management easier. They're primarily designed to lower the chances of poor asthma control and inappropriate therapy on a daily basis.
Due to factors such as increased digitalization in the healthcare sector, favorable government policies, and a flexible regulatory environment, the United States is expected to see profitable growth. Furthermore, rising private and public financing for smart inhalers will help the region grow even faster throughout the predicted period. As a result, such elements are to blame for the market's good expansion in North America. In the United States, rapid adoption of cutting-edge technology and the introduction of new end-user goods are likely to dominate market demand. Following the United States, Canada is represented in the market's top dominant shares. Growing government backing through health-sector investments, as well as improved treatment procedures, outnumbers the industry's demand for smart inhalers.
The US market dominated the North America Smart Inhalers Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $109,928.5 Thousands by 2027. The Canada market is estimated to grow at a CAGR of 26.1% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 25% during (2021 - 2027).
Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Smart Inhalers Market is Estimated to reach $414.4 Million by 2027, at a CAGR of 24.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Metered Dose Inhalers (MDI's)
- Dry Powdered Inhalers (DPIs)
By Disease Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, LLC
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health, Inc.
- Philip Morris International, Inc. (Vectura Group Plc)
- Resmed, Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Smart Inhalers Market, by Product
1.4.2 North America Smart Inhalers Market, by Disease Indication
1.4.3 North America Smart Inhalers Market, by Distribution Channel
1.4.4 North America Smart Inhalers Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
Chapter 4. North America Smart Inhalers Market by Product
4.1 North America Metered Dose Inhalers (MDI's) Market by Country
4.2 North America Dry Powdered Inhalers (DPIs) Market by Country
Chapter 5. North America Smart Inhalers Market by Disease Indication
5.1 North America Asthma Market by Country
5.2 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country
Chapter 6. North America Smart Inhalers Market by Distribution Channel
6.1 North America Hospitals Pharmacies Market by Country
6.2 North America Retail Pharmacies Market by Country
6.3 North America Online Pharmacies Market by Country
Chapter 7. North America Smart Inhalers Market by Country
7.1 US Smart Inhalers Market
7.1.1 US Smart Inhalers Market by Product
7.1.2 US Smart Inhalers Market by Disease Indication
7.1.3 US Smart Inhalers Market by Distribution Channel
7.2 Canada Smart Inhalers Market
7.2.1 Canada Smart Inhalers Market by Product
7.2.2 Canada Smart Inhalers Market by Disease Indication
7.2.3 Canada Smart Inhalers Market by Distribution Channel
7.3 Mexico Smart Inhalers Market
7.3.1 Mexico Smart Inhalers Market by Product
7.3.2 Mexico Smart Inhalers Market by Disease Indication
7.3.3 Mexico Smart Inhalers Market by Distribution Channel
7.4 Rest of North America Smart Inhalers Market
7.4.1 Rest of North America Smart Inhalers Market by Product
7.4.2 Rest of North America Smart Inhalers Market by Disease Indication
7.4.3 Rest of North America Smart Inhalers Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Adherium Limited
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Approvals and Trials:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 Teva Pharmaceutical Industries Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 OPKO Health, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.6 Aptar Group, Inc. (Cohero Health Inc.)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Approvals and Trials:
8.8 ResMed, Inc. (Propeller Health)
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Cognita Labs, LLC
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Approvals and Trials:
8.10. Vectura Group plc (Philip Morris International, Inc.)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
TABLE 1 North America Smart Inhalers Market, 2017 - 2020, USD Thousands
TABLE 2 North America Smart Inhalers Market, 2021 - 2027, USD Thousands
TABLE 3 Partnerships, Collaborations and Agreements– Smart Inhalers Market
TABLE 4 Product Launches And Product Expansions– Smart Inhalers Market
TABLE 5 Acquisition and Mergers– Smart Inhalers Market
TABLE 6 Approvals and trials- smart inhalers market
TABLE 7 North America Smart Inhalers Market by Product, 2017 - 2020, USD Thousands
TABLE 8 North America Smart Inhalers Market by Product, 2021 - 2027, USD Thousands
TABLE 9 North America Metered Dose Inhalers (MDI's) Market by Country, 2017 - 2020, USD Thousands
TABLE 10 North America Metered Dose Inhalers (MDI's) Market by Country, 2021 - 2027, USD Thousands
TABLE 11 North America Dry Powdered Inhalers (DPIs) Market by Country, 2017 - 2020, USD Thousands
TABLE 12 North America Dry Powdered Inhalers (DPIs) Market by Country, 2021 - 2027, USD Thousands
TABLE 13 North America Smart Inhalers Market by Disease Indication, 2017 - 2020, USD Thousands
TABLE 14 North America Smart Inhalers Market by Disease Indication, 2021 - 2027, USD Thousands
TABLE 15 North America Asthma Market by Country, 2017 - 2020, USD Thousands
TABLE 16 North America Asthma Market by Country, 2021 - 2027, USD Thousands
TABLE 17 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2017 - 2020, USD Thousands
TABLE 18 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2021 - 2027, USD Thousands
TABLE 19 North America Smart Inhalers Market by Distribution Channel, 2017 - 2020, USD Thousands
TABLE 20 North America Smart Inhalers Market by Distribution Channel, 2021 - 2027, USD Thousands
TABLE 21 North America Hospitals Pharmacies Market by Country, 2017 - 2020, USD Thousands
TABLE 22 North America Hospitals Pharmacies Market by Country, 2021 - 2027, USD Thousands
TABLE 23 North America Retail Pharmacies Market by Country, 2017 - 2020, USD Thousands
TABLE 24 North America Retail Pharmacies Market by Country, 2021 - 2027, USD Thousands
TABLE 25 North America Online Pharmacies Market by Country, 2017 - 2020, USD Thousands
TABLE 26 North America Online Pharmacies Market by Country, 2021 - 2027, USD Thousands
TABLE 27 North America Smart Inhalers Market by Country, 2017 - 2020, USD Thousands
TABLE 28 North America Smart Inhalers Market by Country, 2021 - 2027, USD Thousands
TABLE 29 US Smart Inhalers Market, 2017 - 2020, USD Thousands
TABLE 30 US Smart Inhalers Market, 2021 - 2027, USD Thousands
TABLE 31 US Smart Inhalers Market by Product, 2017 - 2020, USD Thousands
TABLE 32 US Smart Inhalers Market by Product, 2021 - 2027, USD Thousands
TABLE 33 US Smart Inhalers Market by Disease Indication, 2017 - 2020, USD Thousands
TABLE 34 US Smart Inhalers Market by Disease Indication, 2021 - 2027, USD Thousands
TABLE 35 US Smart Inhalers Market by Distribution Channel, 2017 - 2020, USD Thousands
TABLE 36 US Smart Inhalers Market by Distribution Channel, 2021 - 2027, USD Thousands
TABLE 37 Canada Smart Inhalers Market, 2017 - 2020, USD Thousands
TABLE 38 Canada Smart Inhalers Market, 2021 - 2027, USD Thousands
TABLE 39 Canada Smart Inhalers Market by Product, 2017 - 2020, USD Thousands
TABLE 40 Canada Smart Inhalers Market by Product, 2021 - 2027, USD Thousands
TABLE 41 Canada Smart Inhalers Market by Disease Indication, 2017 - 2020, USD Thousands
TABLE 42 Canada Smart Inhalers Market by Disease Indication, 2021 - 2027, USD Thousands
TABLE 43 Canada Smart Inhalers Market by Distribution Channel, 2017 - 2020, USD Thousands
TABLE 44 Canada Smart Inhalers Market by Distribution Channel, 2021 - 2027, USD Thousands
TABLE 45 Mexico Smart Inhalers Market, 2017 - 2020, USD Thousands
TABLE 46 Mexico Smart Inhalers Market, 2021 - 2027, USD Thousands
TABLE 47 Mexico Smart Inhalers Market by Product, 2017 - 2020, USD Thousands
TABLE 48 Mexico Smart Inhalers Market by Product, 2021 - 2027, USD Thousands
TABLE 49 Mexico Smart Inhalers Market by Disease Indication, 2017 - 2020, USD Thousands
TABLE 50 Mexico Smart Inhalers Market by Disease Indication, 2021 - 2027, USD Thousands
TABLE 51 Mexico Smart Inhalers Market by Distribution Channel, 2017 - 2020, USD Thousands
TABLE 52 Mexico Smart Inhalers Market by Distribution Channel, 2021 - 2027, USD Thousands
TABLE 53 Rest of North America Smart Inhalers Market, 2017 - 2020, USD Thousands
TABLE 54 Rest of North America Smart Inhalers Market, 2021 - 2027, USD Thousands
TABLE 55 Rest of North America Smart Inhalers Market by Product, 2017 - 2020, USD Thousands
TABLE 56 Rest of North America Smart Inhalers Market by Product, 2021 - 2027, USD Thousands
TABLE 57 Rest of North America Smart Inhalers Market by Disease Indication, 2017 - 2020, USD Thousands
TABLE 58 Rest of North America Smart Inhalers Market by Disease Indication, 2021 - 2027, USD Thousands
TABLE 59 Rest of North America Smart Inhalers Market by Distribution Channel, 2017 - 2020, USD Thousands
TABLE 60 Rest of North America Smart Inhalers Market by Distribution Channel, 2021 - 2027, USD Thousands
TABLE 61 Key Information – Adherium Limited
TABLE 62 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 63 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 64 KEY INFORMATION – ASTRAZENECA PLC
TABLE 65 Key Information – OPKO Health, Inc.
TABLE 66 key Information – Aptar Group, Inc.
TABLE 67 Key Information – Novartis AG
TABLE 68 Key Information – ResMed, Inc.
TABLE 69 Key Information – Cognita Labs, LLC
TABLE 70 Key Information – Vectura Group plc
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Recent strategies and developments: Adherium Limited
FIG 4 Recent strategies and developments: AptarGroup, Inc.